The FDA and the Next Wave of Drug Abuse - Proactive Pharmacovigilance

N Engl J Med. 2018 Jul 19;379(3):205-207. doi: 10.1056/NEJMp1806486. Epub 2018 May 30.
No abstract available

MeSH terms

  • Amines / therapeutic use
  • Analgesics, Opioid / adverse effects
  • Analgesics, Opioid / therapeutic use
  • Cyclohexanecarboxylic Acids / therapeutic use
  • Drug Therapy, Combination / adverse effects
  • Drug Utilization / trends
  • Gabapentin
  • Humans
  • Loperamide / adverse effects
  • Loperamide / therapeutic use
  • Opioid-Related Disorders / prevention & control
  • Opioid-Related Disorders / therapy*
  • Pharmacovigilance*
  • Practice Patterns, Physicians' / trends
  • Prescription Drugs / therapeutic use
  • Secologanin Tryptamine Alkaloids / therapeutic use
  • Substance-Related Disorders / prevention & control*
  • United States
  • United States Food and Drug Administration*
  • gamma-Aminobutyric Acid / therapeutic use

Substances

  • Amines
  • Analgesics, Opioid
  • Cyclohexanecarboxylic Acids
  • Prescription Drugs
  • Secologanin Tryptamine Alkaloids
  • gamma-Aminobutyric Acid
  • Gabapentin
  • Loperamide
  • mitragynine